

# Importance of guideline-adherent secondary prevention post-acute coronary-syndromes: The importance of patient uptake and persistence

Székely, Orsolya; Lane, Deirdre; Lip, Gregory

DOI:

[10.1093/eurheartj/ehy308](https://doi.org/10.1093/eurheartj/ehy308)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Székely, O, Lane, D & Lip, G 2018, 'Importance of guideline-adherent secondary prevention post-acute coronary-syndromes: The importance of patient uptake and persistence', *European Heart Journal*, vol. 39, no. 25, pp. 2365-2367. <https://doi.org/10.1093/eurheartj/ehy308>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

Checked for eligibility: 16/05/2018

This is a pre-copyedited, author-produced version of an article accepted for publication in *European Heart Journal* following peer review. The version of record: Orsolya Székely, Deirdre A Lane, Gregory Y H Lip; Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence, *European Heart Journal*, Volume 39, Issue 25, 1 July 2018, Pages 2365–2367 is available online at: <https://doi.org/10.1093/eurheartj/ehy308>

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Editorial

### **Importance of guideline-adherent secondary prevention post-acute coronary-syndromes:**

#### **The importance of patient uptake and persistence**

Orsolya Székely, MD<sup>1</sup>

Deirdre A Lane, PhD<sup>1,2</sup>

Gregory Y H Lip, MD<sup>1,2</sup>

<sup>1</sup> Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom

<sup>2</sup> Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.

#### Corresponding Author:

Prof Gregory YH Lip. Tel: +44 121 5075080; [g.y.h.lip@bham.ac.uk](mailto:g.y.h.lip@bham.ac.uk)

Despite significant improvements over the last two decades in the acute management of patients presenting with acute coronary syndromes (ACS) with the widespread adoption of primary percutaneous coronary intervention, long-term management remains challenging(1). The morbidity burden after ACS is high, as around 20% of survivors experience a subsequent cardiovascular event (recurrent myocardial infarction, stroke or cardiovascular death) during the first 24 months (2) and total mortality rates vary between 19- 22% by 5 years of follow-up (3). Residual cardiovascular risk and high rates of recurrent events generally lead to poor long-term prognosis (4).

Thus, adequate secondary prevention after ACS is crucial in order to prevent further cardiovascular events, disease progression and death, and to improve length and quality of life. Current European guidelines recommend long-term secondary prevention through optimised pharmacological treatments with anti-thrombotic drugs, beta-blockers, lipid-lowering therapy, renin-angiotensin system inhibitors, and comprehensive lifestyle interventions with risk factor management and cardiac rehabilitation (5)(6).

Since adherence to long-term evidence-based therapies among cardiovascular patients is generally poor (7), implementation of innovative strategies, multidisciplinary approaches that may enhance adherence and identification of patients with high risk of non-adherence should be a priority (8). When investigating the persistence with secondary prevention medication in the TRANSLATE-ACS study (prospective observational multicenter study), nearly one-third of the 7955 patients discontinued the prescribed medication by 6 months after ACS (9).

*In this issue of the journal*, Frederiksen *et al.* (10) report their findings from a large, nationwide population-based study, which assessed ethnic differences in the use of preventive pharmacological treatment and non-pharmacological interventions among survivors of ACS by comparing migrants and to Danish-born citizens. From the Danish national registries, they identified 33199 patients, who were discharged from hospital following ACS during 2010-2014, and examined the initiation rates and time to discontinuation of secondary preventive medications, in addition to participation in cardiac rehabilitation programs, determined by number of contacts for the interventions during a 180-days follow-up. They found significantly lower initiation rates of both pharmaceutical treatment and lifestyle interventions in non-Western migrants (Turks and Pakistanis) compared to Danish-born citizens, whereas Western migrants did not differ significantly from those Danish-born. The risk of therapy discontinuation was found to be significantly higher for all medication groups in non-Western migrants compared to those Danish-born. For non-pharmacological interventions, all migrant subgroups showed statistically lower participation.

The study by Frederiksen *et al.* has many positive aspects, including a large cohort size, statistical power and a comprehensive assessment on the use of both pharmacological and lifestyle changing interventional measures. Their findings are some of the first European real-world data on treatment adherence and persistence with secondary prevention post-ACS among migrants, shifting the focus on the causative factors and possible interventional strategies that may enhance patient adherence. Nevertheless, as with most observational studies based on administrative data, there are several limitations that should be recognized (11). For example, there are no data about follow-up visits or monitoring; no evidence about post-discharge

evolution of the disease or treatment-associated complications; new-onset disease(s) which may explain possible contraindications to secondary prevention treatment; no information about patient education and psychological adaptation; or bias and residual confounders from comorbidities.


These findings serve as a reminder that due to mass immigration and significant demographic changes in populations, healthcare systems throughout Europe need to adapt and some ethnic groups may require closer attention and/or specific interventions for both primary and secondary prevention of ACS. The reasons for the differences in treatment initiation and persistence, and participation in non-pharmacological interventions, requires further exploration. It is not possible to ascertain from the nationwide registries if migrants were less likely to be prescribed non-pharmacological lifestyle interventions due to physician-perceived barriers or patient refusal. In the present study (10) Non-Western migrants had less formal education compared to Danish-born citizens and this, along with possible language barriers and socioeconomic factors (i.e., availability of disposable income to participate in required lifestyle changes, healthier food options, access to leisure/exercise facilities, ability to take time off work to attend cardiac rehabilitation (non-Western migrants were of working age), financial contribution to medication (as only part-coverage, etc.) may have contributed to the lower rates of initiation and adherence to secondary prevention among non-Western migrants. Language barriers significantly impair the ability of healthcare professionals to impart patient education and explain the necessity of medication and lifestyle change to patients. Understanding the reasons for the reported differences is important to target interventions appropriately; it may be more beneficial to target public health interventions, for primary and secondary prevention, at the whole Danish

population rather than focusing resources specifically on one group (migrants) but it may be that group-specific interventions are required.

In contrast, real-world data about adherence and persistence to treatments in other chronic conditions, such as oral anticoagulation for stroke prevention in atrial fibrillation (AF), are more variable. High early vitamin K antagonist (VKA) discontinuation rates in some vulnerable patient groups (e.g. elderly, cardiovascular and malignant comorbidities, renal failure) still remain an area of concern, as cessation has been associated with poor clinical outcomes (12). In the era of non-vitamin K oral anticoagulants (NOACs), guideline adherence has improved significantly leading to higher therapy persistence with NOACs than VKA, when compared in a large British cohort of anticoagulation-naïve patients with non-valvular AF (13). Thus, emphasises the importance of patient education and proposes a well-structured follow-up system, which may serve as a practical model for implementation of, and to, improve cardiovascular treatment adherence in other fields (14).

For future considerations, it is essential to identify health-system related difficulties and weaknesses in the management and support of secondary prevention post-ACS discharge, but also socioeconomic- and patient-related factors including education level, language barriers, immigrant status, financial concerns should be taken into consideration to optimise treatment adherence [Figure]. Proper utilization and adherence to evidence-based treatment strategies and interventions has to be the priority after acute coronary syndromes in order to improve long-term outcomes.

Figure 1. Strategies to improve patients' treatment adherence and persistence



## References

1. Sibbing D, Angiolillo DJ, Huber K. Antithrombotic therapy for acute coronary syndrome: Past, present and future. *Thromb Haemost* [Internet]. 2017 Nov 9 [cited 2018 Apr 18];117(7):1240–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28594051>
2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective. *European Heart Journal*. 2015. p. 1163–1170a.
3. Fox KAA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, et al. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study). *Eur Heart J*. 2010;31(22):2755–64.
4. Piironen M, Ukkola O, Huikuri H, Havulinna AS, Koukkunen H, Mustonen J, et al. Trends in long-term prognosis after acute coronary syndrome. *Eur J Prev Cardiol*. 2017;24(3).
5. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European Heart Journal*. 2018. p. 119–77.
6. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2015;32(23):2999–3054.
7. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients. *Am J Med*. 2012;125(9):882–7.
8. Piepoli MF, Corrà U, Abreu A, Cupples M, Davos C, Doherty P, et al. Challenges in secondary prevention of cardiovascular diseases: A review of the current practice. *Int J*



- Cardiol. 2015;180:114–9.
9. Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. *Am Heart J.* 2015;170(1):62–9.
  10. Frederiksen HW, Zwisler A, Johnsen SP, Öztürk B, Lindhardt T, Norredam M. Differences in initiation and discontinuation of preventive medications and use of non-pharmacological interventions after acute coronary syndrome among migrants and Danish born. *Eur Hear J.* 2018;IN PRESS.
  11. Freedman B, Lip GYH. “Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation. *Thromb Haemost.* 2016;116(4).
  12. Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. *Thromb Haemost.* 2017 Mar;117(6).
  13. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. *Thromb Haemost* [Internet]. 2016 Jan 6;115(1):31–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26246112>
  14. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J.* 2018;(March):1–64.